NMD4C Launch Canadian Neuromuscular Clinical Trial Network
The Neuromuscular Disease Network for Canada is thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work. Led by investigators Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, the CTN will work towards increasing the number of neuromuscular clinical trials conducted in Canada, enhancing Canadian neuromuscular trial capacity, and supporting a cohesive network of clinician researchers and their teams.
Increasing the number of neuromuscular clinical trials conducted in Canada
The CTN will facilitate connections between industry and clinical sites to support the activation of new clinical trials or the opening of new clinical trial sites. We will deliver information about upcoming neuromuscular trial opportunities and offer information on existing trials available and implement strategic promotion to increase international visibility of the benefits of conducting neuromuscular clinical trials in Canada.
Enhancing trial capacity
The CTN will offer education and training programs to clinicians and their teams to improve clinical trial execution, connect with existing patient organizations to increase opportunities for patients to participate in neuromuscular clinical trials, and gather patient feedback from patient organizations and clinical sites to advance the development of patient-centric clinical trials.
Supporting a network of clinician researchers and their teams
The CTN will facilitate peer-to-peer mentorship opportunities among trialists specializing in neuromuscular clinical trials, coordinate a pan-Canadian hub for trialists and their teams to discuss clinical trial experiences, and launch a Canada-wide community of practice program for clinical trial coordinators overseeing neuromuscular clinical trials.
The CTN leadership group will be supported by Maria Masnata, our new clinical trials and community of practice manager. Learn more about the CTN mission and objectives, or contact Maria Masnata for more information!
Read next...
You Can Now Find NMD4C on Bluesky
We’re moving to Bluesky! The NMD4C will now share updates on Bluesky instead of X. Please consider following us at @nmd4c.ca to stay connected!
CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces
The NMD4C is excited to share that network investigators have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies.
NMD4C Presents the 2025 Early Career Award Recipients
We are excited to announce the recipients of the 2025 NMD4C Early Career Awards! This is the third year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.
Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy
Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.
New Content Available in LEARNMD
LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!
Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group
We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C